Evoke Pharma announced that it has initiated a Phase 2b Metoclopramide Intranasal Trial (MINT) to evaluate EVK-001 for the treatment of adults with symptoms of diabetic gastroparesis. The clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of two doses of EVK-001 over 4 weeks in 225 adult patients at over 25 clinical sites in the U.S.
EVK-001 is a proprietary formulation of metoclopramide that has been optimized for intranasal delivery and tolerability. Unlike tablet formulations, EVK-001 is designed to deliver a systemic dose of metoclopramide that does not depend on absorption from the gastrointestinal (GI) tract.
For more information call (858) 967-5454 or visit www.evokepharma.com.